Analysis of the correlation between P53 and Cox-2 expression and prognosis in esophageal cancer

Chen,Jun; Wu,Fang; Pei,Hong‑Lei; Gu,Wen‑Dong; Ning,Zhong‑Hua; Shao,Ying‑Jie; Huang,Jin

doi:10.3892/ol.2015.3624

Analysis of the correlation between P53 and Cox-2 expression and prognosis in esophageal cancer

Authors:
- Jun Chen
- Fang Wu
- Hong‑Lei Pei
- Wen‑Dong Gu
- Zhong‑Hua Ning
- Ying‑Jie Shao
- Jin Huang
View Affiliations

Affiliations: Department of Radiation Oncology, The Third Affiliated Hospital, Soochow University, Changzhou, Jiangsu 213003, P.R. China, Department of Oncology, The Third Affiliated Hospital, Soochow University, Changzhou, Jiangsu 213003, P.R. China
Published online on: August 19, 2015 https://doi.org/10.3892/ol.2015.3624
Pages: 2197-2203
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to explore the importance of P53 and Cox-2 protein expression in esophageal cancer and assess their influence on prognosis. The expression of P53 and Cox-2 was assessed in esophageal cancer samples from 195 patients subjected to radical surgery at Changzhou First People's Hospital (Changzhou, China) between May 2010 and December 2011. Expression of P53 and Cox‑2 proteins were detected in 60.5% (118/195) and 69.7% (136/195) of the samples, respectively, and were co‑expressed in 43.1% (84/195) of the samples. A correlation was identified between P53 expression and overall survival (OS) (P=0.0351) as well as disease‑free survival (DFS) (P=0.0307). In addition, the co‑expression of P53 and Cox‑2 also correlated with OS (P=0.0040) and DFS (P=0.0042). P53 expression (P=0.023), TNM staging (P<0.001) and P53/Cox‑2 co‑expression (P=0.009) were identified as independent factors affecting OS in patients with esophageal cancer via a Cox multivariate regression model analysis. A similar analysis also identified P53 expression (P=0.020), TNM staging (P<0.001) and P53/Cox‑2 co‑expression (P=0.008) as independent prognostic factors influencing DFS in these patients. Binary logistic regression analysis demonstrated a correlation between P53 expression (P=0.012), TNM staging (P<0.001), tumor differentiation level (P=0.023) and P53/Cox‑2 co‑expression (P=0.021), and local recurrence or distant esophageal cancer metastasis. The results of the present study indicate that P53 and Cox‑2 proteins may act synergistically in the development of esophageal cancer, and the assessment of P53/Cox‑2 co‑expression status in esophageal cancer biopsies may become an important diagnostic criterion to evaluate the prognosis of patients with esophageal cancer.

View Figures

View References

1	Huang JX, Chen WC, Lin M, Zhang YL, Li FY, Song ZX, Xiao W, Chen P, Qian RY, Salminen E, et al: Clinicopathological significance of cyclooxygenase-2 and cell cycle-regulatory proteins expression in patients with esophageal squamous cell carcinoma. Dis Esophagus. 25:121–129. 2012. View Article : Google Scholar : PubMed/NCBI
2	Meng XY, Zhu ST, Zong Y, Wang YJ, Li P and Zhang ST: Promoter hypermethylation of cyclooxygenase-2 gene in esophageal squamous cell carcinoma. Dis Esophagus. 24:444–449. 2011. View Article : Google Scholar : PubMed/NCBI
3	Surget S, Khoury MP and Bourdon JC: Uncovering the role of p53 splice variants in human malignancy: A clinical perspective. Onco Targets Ther. 7:57–68. 2014.
4	Chandrasekharan NV and Simmons DL: The cyclooxygenases. Genome Biol. 5:2412004. View Article : Google Scholar : PubMed/NCBI
5	Chen LQ: Understanding and appraisal of the new TNM classification for esophageal cancer in the AJCC cancer staging manual (7th edition). Zhonghua Zhong Liu Za Zhi. 32:237–240. 2010.(In Chinese). PubMed/NCBI
6	Kang SY, Halvorsen OJ, Gravdal K, Bhattacharya N, Lee JM, Liu NW, Johnston BT, Johnston AB, Haukaas SA, Aamodt K, et al: Prosaposin inhibits tumor metastasis via paracrine and endocrine stimulation of stromal p53 and Tsp-1. Proc Natl Acad Sci USA. 106:12115–12120. 2009. View Article : Google Scholar : PubMed/NCBI
7	Huang H, Wang LF, Tian HM, Liu Y, Li M, Qu P, Wang WR and Zhang W: Expression of retinoic acid receptor-beta mRNA and p16, p53, Ki67 proteins in esophageal carcinoma and its precursor lesions. Zhonghua Zhong Liu Za Zhi. 27:152–155. 2005.(In Chinese). PubMed/NCBI
8	Do PM, Varanasi L, Fan SQ, Li CY, Kubacka I, Newman V, Chauhan K, Daniels SR, Boccetta M, Garrett MR, et al: Mutant p53 cooperates with ETS2 to promote etoposide resistance. Genes Dev. 26:830–845. 2012. View Article : Google Scholar : PubMed/NCBI
9	Lee MH and Lozano G: Regulation of the p53-MDM2 pathway by 14-3-3 and other proteins. Semin Cancer Biol. 16:225–234. 2006. View Article : Google Scholar : PubMed/NCBI
10	Kirsch DG and Kastan MB: Tumor-suppressor p53: Implications for tumor development and prognosis. J Clin Oncol. 16:3158–3168. 1998.PubMed/NCBI
11	Fagundes RB, Mello CR, Tollens P, Pütten ACK, Wagner MB, Moreira LF and Barros SG: P53 protein in esophageal mucosa of individuals at high risk of squamous cell carcinoma of the esophagus. Dis Esophagus. 14:185–190. 2001. View Article : Google Scholar : PubMed/NCBI
12	Han U, Can OI, Han S, Kayhan B and Onal BU: Expressions of p53, VEGF C, p21: Could they be used in preoperative evaluation of lymph node metastasis of esophageal squamous cell carcinoma? Dis Esophagus. 20:379–385. 2007. View Article : Google Scholar : PubMed/NCBI
13	Ye B, Wang X, Yang Z, Sun Z, Zhang R, Hu Y, Lu Y and Du J: P53 and p73 expression in esophageal carcinoma correlate with clinicopathology of tumors. Hepatogastroenterology. 59:2192–2195. 2012.PubMed/NCBI
14	Chino O, Kijima H, Shimada H, Nishi T, Tanaka H, Kise Y, Kenmochi T, Himeno S, Machimura T, Tanaka M, et al: Accumulation of p53 in esophageal squamous cell carcinoma. Int J Mol Med. 8:359–363. 2001.PubMed/NCBI
15	Jin Y, Zhang W and Liu B: Abnormal expression of p53, Ki67 and iNOS in human esophageal carcinoma in situ and pre-malignant lesions. Zhonghua Zhong Liu Za Zhi. 23:129–131. 2001.(In Chinese). PubMed/NCBI
16	Feletou M, Huang Y and Vanhoutte PM: Endothelium-mediated control of vascular tone: COX-1 and COX-2 products. Br J Pharmacol. 164:894–912. 2011. View Article : Google Scholar : PubMed/NCBI
17	O'Banion MK: Cyclooxygenase-2: Molecular biology, pharmacology, and neurobiology. Crit Rev Neurobiol. 13:45–82. 1999.PubMed/NCBI
18	Williams CS and DuBois RN: Prostaglandin endoperoxide synthase: Why two isoforms? Am J Physiol. 270:G393–G400. 1996.PubMed/NCBI
19	Willoughby DA, Moore AR and Colville-Nash PR: COX-1, COX-2 and COX-3 and the future treatment of chronic inflammatory disease. Lancet. 355:646–648. 2000. View Article : Google Scholar : PubMed/NCBI
20	Xin X, Majumder M, Girish GV, Mohindra V, Maruyama T and Lala PK: Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model. Lab Invest. 92:1115–1128. 2012. View Article : Google Scholar : PubMed/NCBI
21	Misra S and Sharma K: COX-2 signaling and cancer: New players in old arena. Curr Drug Targets. 15:347–359. 2014. View Article : Google Scholar : PubMed/NCBI
22	Okumura H, Uchikado Y, Setoyama T, Matsumoto M, Owaki T, Ishigami S and Natsugoe S: Biomarkers for predicting the response of esophageal squamous cell carcinoma to neoadjuvant chemoradiation therapy. Surg Today. 44:421–428. 2014. View Article : Google Scholar : PubMed/NCBI
23	Kashiwagi S, Hosono K, Suzuki T, Takeda A, Uchinuma E and Majima M: Role of COX-2 in lymphangiogenesis and restoration of lymphatic flow in secondary lymphedema. Lab Invest. 91:1314–1325. 2011. View Article : Google Scholar : PubMed/NCBI
24	Zhou BT, Yang W, Xu XH, Ai YG, Li XL and Huang YJ: Correlation of cyclooxygenase 2 expression with microlymphatic density and its clinical significance. Zhonghua Wei Chang Wai Ke Za Zhi. 13:699–702. 2010.(In Chinese). PubMed/NCBI
25	Prins MJ, Verhage RJ, ten Kate FJ and van Hillegersberg R: Cyclooxygenase isoenzyme-2 and vascular endothelial growth factor are associated with poor prognosis in esophageal adenocarcinoma. J Gastrointest Surg. 16:956–966. 2012. View Article : Google Scholar : PubMed/NCBI
26	Benoit V, de Moraes E, Dar NA, Taranchon E, Bours V, Hautefeuille A, Tanière P, Chariot A, Scoazec JY, de Moura Gallo CV, et al: Transcriptional activation of cyclooxygenase-2 by tumor suppressor p53 requires nuclear factor-kappaB. Oncogene. 25:5708–5718. 2006. View Article : Google Scholar : PubMed/NCBI
27	Song J, Wei Y, Chen Q and Xing D: Cyclooxygenase 2-mediated apoptotic and inflammatory responses in photodynamic therapy treated breast adenocarcinoma cells and xenografts. J Photochem Photobiol B. 134:27–36. 2014. View Article : Google Scholar : PubMed/NCBI
28	Cheng AS, Yu J, Lai PB, Chan HL and Sung JJ: Cox-2 mediates hepatitis B virus X protein abrogation of p53-induced apoptosis. Biochem Biophys Res Commun. 374:175–180. 2008. View Article : Google Scholar : PubMed/NCBI
29	Choi EM, Kim SR, Lee EJ and Han JA: Cyclooxygenase-2 functionally inactivates p53 through a physical interaction with p53. Biochim Biophys Acta. 1793:1354–1365. 2009. View Article : Google Scholar : PubMed/NCBI
30	Ma XL, XS G and Sun HJ: Advance in research on relations between cyclooxygenase-2 and P53 during inflammatory stress and carcinogenesis. Int J Genet. 32:372–376. 2009.(In Chinese).